NVO Articles, Novo Nordisk A/S - From 03/11/24

In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic (semaglutide), Novo Nordis...

Novo Nordisk A/S’s (NYSE:NVO) head of development, Martin Holst Lange, expressed strong confidence in the drugmaker’s ability...

Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...

A new study found that the interaction between cannabis and popular weight-loss drugs such as Ozempic and Wegovy can have an impact on a common tes...

Thursday, Evernorth Health Services, a subsidiary of Cigna Group (NYSE:CI) introduced a financial guarantee within its EncircleRx pr...

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. Shares of American Eagle Outfitters, Inc. (NYSE: AEO) ...

Thursday, Novo Nordisk A/S (NYSE:NVO) is holding its Capital Markets Day. Its executive management and other members of senior management...

Ozempic maker Novo Nordisk (NYSE:NVO), a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in re...

The weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease, a...

Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound...